MetLife's Q2 Earnings Beat Reaffirms The Buy Case As Organic Growth Stands Out

MetLife, Inc. is reaffirmed as a Buy, with quality fundamentals, strong organic growth, and a resilient dividend profile supporting continued bullish momentum. MET's diversified business model, including investment management and group benefits, drives organic growth across multiple segments despite modest profit margin expansion. The balance sheet boasts A-level credit ratings and modest leverage, but significant fixed-income exposure introduces interest rate risk, warranting ongoing monitoring.